本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Oncolytics Biotech Inc

0.7806
+0.00060.08%
成交量:21.27萬
成交額:16.61萬
市值:9,953.47萬
市盈率:-2.43
高:0.7840
開:0.7832
低:0.7780
收:0.7800
52周最高:1.51
52周最低:0.7301
股本:1.28億
流通股本:1.23億
量比:1.61
換手率:0.17%
股息:- -
股息率:- -
每股收益(TTM):-0.3215
每股收益(LYR):-0.3000
淨資產收益率:-10187.64%
總資產收益率:-211.24%
市淨率:-16.14
市盈率(LYR):-2.60

資料載入中...

2026/04/01

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/03/31

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/03/20

重要事件披露

Form 8-K - Current report
2026/03/19

重要事件披露

Form 8-K - Current report
2026/03/02

重要事件披露

Form 8-K - Current report
2026/02/24

重要事件披露

Form 8-K - Current report
2026/02/04

重要事件披露

Form 8-K - Current report
2026/01/15

重要事件披露

Form 8-K - Current report
2026/01/15

重要事件披露

Form 8-K - Current report
2026/01/12

重要事件披露

Form 8-K - Current report
2026/01/09

企業合併公告

Form 425 - Prospectuses and communications, business combinations
2025/12/06

SEC問詢函

Form CORRESP - Correspondence
2025/08/28

SEC問詢函

Form CORRESP - Correspondence
2025/03/07

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/06/04

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/12

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/03/03

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/03/03

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/05

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/05

財報披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]